In this episode, Dr. Adam Luginbuhl, Dr. Dylan Roden, and Dr. Ravindra Uppaluri discuss the implementation of neoadjuvant immunotherapy in head and neck cancer, focusing on indications, patient selection, and lessons from recent trials such as Keynote-689. Through detailed case discussions, they examine the intent behind neoadjuvant therapy, real-world patient counseling, and how to balance enthusiasm for promising responses with realistic clinical expectations. The conversation highlights how immunotherapy may reshape preoperative strategies while underscoring the importance of surgical planning and multidisciplinary coordination.
Contributors:
Dr. Adam Luginbuhl is an Associate Professor of Otolaryngology Head and Neck Surgery at Thomas Jefferson University.
Dr. Dylan Roden is a head and neck cancer surgeon and Chair of Robotic Surgery at Rutgers New Jersey Medical School.
Dr. Ravindra Uppaluri is the Director of Head and Neck Surgical Oncology at the Brigham and Women’s Hospital in Boston, Massachusetts.
